ABIM MOC Part 2 • CME

January 6 • 4:00 – 5:00

Melanoma: A Case-Based Tour in 2026
Frances Collichio, MD
 

ABIM MOC Part 2 • CME

January 20 • 4:00 – 5:00

ctDNA and Lung Cancer
Maximilian Diehn, MD, PhD
 

ABIM MOC Part 2 • CME

February 3 • 4:00 – 5:00

Advances in CART Therapy for Lymphoma
Natalie Grover, MD
 

ABIM MOC Part 2 • CME

February 17 • 4:00 – 5:00

Clinical Trials in Older Multiple Myeloma
Ashley E. Rosko, MD
 

ABIM MOC Part 2 • CME

March 3 • 4:00 – 5:00

Tailoring Treatment Intensity in HNSCC: The Expanding Role of Cancer Immunotherapy
Robert L. Ferris, MD, PhD, FACS

Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed.

ABIM MOC Part 2 • CME

March 17 • 4:00 – 5:00

Surgical Management Limited Stage Breast Cancer
Meghan Flanagan, MD, MPH
 

ABIM MOC Part 2 • CME

April 21 • 4:00 – 5:00

ctDNA, Immunotherapy/Biomarkers in Colorectal Cancer
Chris Lieu, MD

ctDNA, Immunotherapy in colorectal Cancer (MSI, MSS), biomarkers in colorectal cancer

ABIM MOC Part 2 • CME

May 5 • 4:00 – 5:00

Sarcoma
Theodore (Ted) Yanagihara, MD, PhD